ArticleEndocrinology and metabolism (Seoul, Korea)2014
Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer.
Article in Endocrinology and metabolism (Seoul, Korea), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.Oncology reviews · 2026Pooled it
- Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.Cancer chemotherapy and pharmacology · 2015Trial
- Article
- Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience.Cancer management and research · 2021Article
- Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Papillary thyroid carcinoma with hyperthyroidism and multiple metastases: A case report.Medicine · 2020Article
- Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2020Article
- Reply to "Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma".Diagnostics (Basel, Switzerland) · 2020Article
- Observational
- Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer.Endocrinology, diabetes & metabolism case reports · 2019Article
- Skeletal muscle metastases from papillary and follicular thyroid carcinomas: An extensive review of the literature.Oncology letters · 2018Article
- Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFThyroid : official journal of the American Thyroid Association · 2017Article
- Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report.Oncology letters · 2017Article
- Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare.Case reports in obstetrics and gynecology · 2017Article
- Optimal differentiated thyroid cancer management in the elderly.Drugs & aging · 2015Review
- Articles in 'endocrinology and metabolism' in 2014.Endocrinology and metabolism (Seoul, Korea) · 2015Article
- Treatment of distant metastases from follicular cell-derived thyroid cancer.F1000prime reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed. Treatment with sorafenib was begun in September 2010. After 11 months treatment of sorafenib, newly developed metastatic lesions were found in mediastinal lymph nodes, liver, and bones. Considered as treatment failure, the administration of sorafenib was discontinued. Two weeks after sorafenib treatment was stopped, the disease progressed abruptly and caused death of the patient by respiratory failure. In our patient, PTC progressed rapidly after the cessation of sorafenib treatment. Patients with several other types of cancer have also experienced such rapid disease progression, termed "flare-ups." Physicians should be aware that flare-ups may occur in advanced PTC patients following the cessation of TKI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.